mAKAP-orchestrated phosphorylation events: regulation of PDE4D3

mAKAP 精心策划的磷酸化事件:PDE4D3 的调节

基本信息

项目摘要

DESCRIPTION (provided by applicant): cAMP is an important second messenger that regulates several physiological events in the heart including contraction, metabolism and gene transcription. Several recent studies have illustrated not only the importance of phosphodiesterases (PDE) for the control of basal cAMP levels in the heart, but also in the regulation of localized changes of cAMP due to the cellular location of PDEs. Therefore, identifying the molecular determinants governing PDE localization and activity, as well as the biological processes attributed to each PDE, will further our knowledge of cAMP signaling in the heart. We have previously described a scaffolding protein that sequesters the phosphodiesterase PDE4D3 to the nuclear envelope in differentiated cardiac myocytes. The A-Kinase Anchoring Protein mAKAP maintains a complex consisting of the cAMP-dependent protein kinase, PDE4D3, the Map Kinase ERK5, the guanine nucleotide exchange factor Epac, the protein phosphatase 2A, and the Ryanodine Receptor. Previous data has shown mAKAP orchestrated both ERK5 and PKA regulation of PDE4D3. These phosphorylation-induced changes in PDE4D3 activity will in turn modulate the concentration of cAMP surrounding the complex, ultimately regulating all cAMP effectors in the complex, namely PKA, PDE4D3 and Epac. The three Specific Aims of this proposal will try to 1) elucidate the physiological events that regulate PDE4D3 phosphorylation regulate cAMP concentration and the phosphorylation state of the Ryanodine Receptor 2) determine the functional consequence of PDE4D3 phosphorylation on Epac-mediated ERK5 activity and ERK5-mediated cardiac hypertrophy, and 3) identify the phosphatase in the complex that governs dephosphorylation of the PDE. Heart disease is the number one cause of death in the United States. Cardiac hypertrophy is the major compensatory mechanism by which the heart responds to a continued, increased demand for cardiac output. Ultimately, cardiac hypertrophy leads to progression into cardiac disease and to heart failure. However, several studies have shown that inhibition of cardiac hypertrophy lowers the risk of death and progression into heart failure. This study will further our understanding of the molecular mechanism of cardiac hypertrophy and help to identify novel targets for drug design to aid in the treatment of hypertrophy.
描述(申请人提供):cAMP是一种重要的第二信使,调节心脏的几个生理事件,包括收缩、新陈代谢和基因转录。最近的一些研究表明,磷酸二酯酶(PDE)不仅对心脏基础cAMP水平的控制具有重要意义,而且还由于PDE的细胞位置而调节cAMP的局部变化。因此,确定控制PDE定位和活性的分子决定因素,以及每个PDE所涉及的生物学过程,将有助于我们进一步了解心脏中的cAMP信号。我们之前已经描述了一种支架蛋白,它将磷酸二酯酶PDE4D3隔离到分化的心肌细胞的核膜上。A-激酶锚定蛋白mAKAP由cAMP依赖的蛋白激酶PDE4D3、Map Kinase ERK5、鸟嘌呤核苷酸交换因子EPAC、蛋白磷酸酶2A和Ryanodine受体组成的复合体。先前的数据表明,mAKAP协调了PDE4D3的ERK5和PKA调控。这些磷酸化诱导的PDE4D3活性变化将反过来调节复合体周围cAMP的浓度,最终调节复合体中的所有cAMP效应物,即PKA、PDE4D3和EPAC。这一建议的三个具体目的将试图1)阐明调节PDE4D3磷酸化的生理事件调节cAMP浓度和Ryanodine受体的磷酸化状态2)确定PDE4D3磷酸化对EPAC介导的ERK5活性和ERK5介导的心肌肥大的功能后果,以及3)确定调控PDE去磷酸化的复合体中的磷酸酶。心脏病是美国的头号死因。心脏肥大是心脏对持续增加的心输出量需求做出反应的主要代偿机制。最终,心肌肥厚会导致心脏病和心力衰竭的进展。然而,一些研究表明,抑制心肌肥厚可以降低死亡和进展为心力衰竭的风险。这项研究将进一步加深我们对心肌肥厚分子机制的理解,并有助于为药物设计寻找新的靶点,以帮助治疗肥厚。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kimberly L Dodge-Kafka其他文献

Kimberly L Dodge-Kafka的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kimberly L Dodge-Kafka', 18)}}的其他基金

Perinuclear Ryanodine Receptors and Cardiac Remodeling
核周瑞尼丁受体与心脏重塑
  • 批准号:
    10733027
  • 财政年份:
    2023
  • 资助金额:
    $ 36.04万
  • 项目类别:
Perinuclear Signaling and Cardiac Hypertrophy
核周信号传导和心脏肥大
  • 批准号:
    10372219
  • 财政年份:
    2021
  • 资助金额:
    $ 36.04万
  • 项目类别:
Perinuclear Signaling and Cardiac Hypertrophy
核周信号传导和心脏肥大
  • 批准号:
    10210654
  • 财政年份:
    2021
  • 资助金额:
    $ 36.04万
  • 项目类别:
Perinuclear Signaling and Cardiac Hypertrophy
核周信号传导和心脏肥大
  • 批准号:
    10593965
  • 财政年份:
    2021
  • 资助金额:
    $ 36.04万
  • 项目类别:
Regulation of Histone Deacetylases by mAKAP Signalosomes
mAKAP 信号小体对组蛋白脱乙酰酶的调节
  • 批准号:
    10308025
  • 财政年份:
    2018
  • 资助金额:
    $ 36.04万
  • 项目类别:
Anchored Phosphatase and Transcription Factor Regulation in the Heart
锚定磷酸酶和转录因子在心脏中的调节
  • 批准号:
    9412882
  • 财政年份:
    2016
  • 资助金额:
    $ 36.04万
  • 项目类别:
Anchored Phosphatase and Transcription Factor Regulation in the Heart
锚定磷酸酶和转录因子在心脏中的调节
  • 批准号:
    9208794
  • 财政年份:
    2016
  • 资助金额:
    $ 36.04万
  • 项目类别:
The Role of Perinuclear Calcium for The induction of Cardiac Hypertrophy
核周钙在诱导心肌肥厚中的作用
  • 批准号:
    9405648
  • 财政年份:
    2016
  • 资助金额:
    $ 36.04万
  • 项目类别:
mAKAP-orchestrated phosphorylation events: regulation of PDE4D3
mAKAP 精心策划的磷酸化事件:PDE4D3 的调节
  • 批准号:
    7243450
  • 财政年份:
    2006
  • 资助金额:
    $ 36.04万
  • 项目类别:
mAKAP-orchestrated phosphorylation events: regulation of PDE4D3
mAKAP 精心策划的磷酸化事件:PDE4D3 的调节
  • 批准号:
    7433739
  • 财政年份:
    2006
  • 资助金额:
    $ 36.04万
  • 项目类别:

相似海外基金

Bridging the Gap: Next-Gen Tools for Accurate Prediction of Disordered Protein Binding Sites
弥合差距:准确预测无序蛋白质结合位点的下一代工具
  • 批准号:
    24K15172
  • 财政年份:
    2024
  • 资助金额:
    $ 36.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Design of protein crystal templates with multiple binding sites for tracking metal complex reactions.
设计具有多个结合位点的蛋白质晶体模板,用于跟踪金属络合物反应。
  • 批准号:
    23K04928
  • 财政年份:
    2023
  • 资助金额:
    $ 36.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Dynamic changes in PIP2 binding sites and their impact on axonal targeting and function of epilepsy-associated KCNQ/Kv7 channels
PIP2 结合位点的动态变化及其对癫痫相关 KCNQ/Kv7 通道的轴突靶向和功能的影响
  • 批准号:
    10744934
  • 财政年份:
    2023
  • 资助金额:
    $ 36.04万
  • 项目类别:
Computational methods to identify small molecule RNA binding sites
识别小分子 RNA 结合位点的计算方法
  • 批准号:
    573688-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 36.04万
  • 项目类别:
    University Undergraduate Student Research Awards
Identification of potential drug binding sites within allosteric networks in cyclic nucleotide modulated channels
环核苷酸调节通道变构网络内潜在药物结合位点的鉴定
  • 批准号:
    10704557
  • 财政年份:
    2022
  • 资助金额:
    $ 36.04万
  • 项目类别:
Identification of potential drug binding sites within allosteric networks in cyclic nucleotide modulated channels
环核苷酸调节通道变构网络内潜在药物结合位点的鉴定
  • 批准号:
    10537846
  • 财政年份:
    2022
  • 资助金额:
    $ 36.04万
  • 项目类别:
Identifying new types of inhibitors in quinone binding sites in photosynthetic enzymes
鉴定光合酶醌结合位点的新型抑制剂
  • 批准号:
    2753921
  • 财政年份:
    2022
  • 资助金额:
    $ 36.04万
  • 项目类别:
    Studentship
Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites
开发针对不同冠状病毒受体结合位点的广泛纳米疫苗
  • 批准号:
    10328140
  • 财政年份:
    2022
  • 资助金额:
    $ 36.04万
  • 项目类别:
Exploiting Water Network Perturbations in Protein Binding Sites
利用蛋白质结合位点的水网络扰动
  • 批准号:
    10621368
  • 财政年份:
    2021
  • 资助金额:
    $ 36.04万
  • 项目类别:
SBIR Phase I: Nonlinear optical method for identifying protein-ligand binding sites
SBIR 第一阶段:识别蛋白质-配体结合位点的非线性光学方法
  • 批准号:
    2111821
  • 财政年份:
    2021
  • 资助金额:
    $ 36.04万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了